

Sara Ghorashian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3140092/publications.pdf>

Version: 2024-02-01

32
papers

1,889
citations

759233

12
h-index

477307

29
g-index

33
all docs

33
docs citations

33
times ranked

2927
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	707
2	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. <i>Nature Medicine</i> , 2019, 25, 1408-1414.	30.7	394
3	A guide to manufacturing CAR T cell therapies. <i>Current Opinion in Biotechnology</i> , 2018, 53, 164-181.	6.6	262
4	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1797-1805.	30.7	125
5	OX40- and CD27-Mediated Costimulation Synergizes with Anti-PD-L1 Blockade by Forcing Exhausted CD8+ T Cells To Exit Quiescence. <i>Journal of Immunology</i> , 2015, 194, 125-133.	0.8	65
6	Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. <i>Nature Cancer</i> , 2021, 2, 629-642.	13.2	59
7	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 3855-3868.	8.2	52
8	Blinatumomab for infant acute lymphoblastic leukemia. <i>Blood</i> , 2020, 135, 1501-1504.	1.4	43
9	Redirection to the bone marrow improves T cell persistence and antitumor functions. <i>Journal of Clinical Investigation</i> , 2018, 128, 2010-2024.	8.2	39
10	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
11	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. <i>British Journal of Haematology</i> , 2020, 190, e274-e276.	2.5	20
12	CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor. <i>Journal of Immunology</i> , 2015, 194, 1080-1089.	0.8	19
13	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668.	5.2	11
14	Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency. <i>Blood Advances</i> , 2021, 5, 2153-2155.	5.2	8
15	A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL. <i>Blood</i> , 2017, 130, 806-806.	1.4	8
16	Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 299-301.	2.4	8
17	Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. <i>Haematologica</i> , 2016, 101, 482-490.	3.5	6
18	Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. <i>Experimental Hematology</i> , 2018, 66, 5-16.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 805-811.	2.5	5
20	Nanobody Based Tri-Specific Chimeric Antigen Receptor to Treat Acute Myeloid Leukaemia. <i>Blood</i> , 2020, 136, 10-11.	1.4	5
21	T cell gene-engineering to enhance GVT and suppress GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 421-433.	1.7	4
22	Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy. <i>Blood</i> , 2021, 138, 1743-1743.	1.4	4
23	The Enhanced Functionality of Low-Affinity CD19 CAR T Cells Is Associated with Activation Priming and Polyfunctional Cytokine Phenotype. <i>Blood</i> , 2020, 136, 52-53.	1.4	3
24	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement. <i>Blood</i> , 2020, 136, 1-1.	1.4	2
25	Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans. <i>Blood</i> , 2019, 134, 52-52.	1.4	2
26	Intention to Treat Analysis of Real-World Outcomes Following Tisagenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. <i>Blood</i> , 2020, 136, 18-19.	1.4	2
27	Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7573.	4.1	2
28	Siglec-6 CAR T: magic bullet for a moving target. <i>Blood</i> , 2021, 138, 1786-1787.	1.4	1
29	Rare Sequences Make Sense of CAR T-cell Therapy Outcomes. <i>Blood Cancer Discovery</i> , 2022, 3, 2-4.	5.0	1
30	The role of immunotherapy in relapse/refractory precursor acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults. <i>British Journal of Haematology</i> , 2021, 192, e42-e44.	2.5	0
31	Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden. <i>Blood</i> , 2018, 132, 5201-5201.	1.4	0
32	A High Sensitivity aCD22 CAR Combined with aCD19 CAR to Generate Dual Targeting CAR T Cells for the Treatment of r/r B-ALL. <i>Blood</i> , 2021, 138, 1710-1710.	1.4	0